Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Molecular Carcinogenesis|December 25, 2019
PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathwayYiliao Luo, Mengxing Li, Uday P Pratap, et al.
Breast Cancer Research and Treatment|October 15, 2020
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancerMei Zhou, Prabhakar Pitta Venkata, Suryavathi Viswanadhapalli, et al.
Breast Cancer Research : BCR|April 9, 2022
SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistanceZexuan Liu, Junhao Liu, Behnam Ebrahimi, et al.
Molecular Cancer Therapeutics|July 26, 2023
Preclinical Development of Brain Permeable ERβ Agonist for the Treatment of GlioblastomaUday P Pratap, Michael Tidwell, Henriette U Balinda, et al.
Cancer Research Communications|September 11, 2024
PELP1 Is a Novel Therapeutic Target in Hepatocellular CarcinomaKhaled Mohamed Nassar, Xue Yang, Adriana Baker, et al.
Molecular Oncology|October 19, 2023
PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesisXue Yang, Zexuan Liu, Weiwei Tang, et al.
Biomolecules|March 28, 2026
Targeting LIPA with ERX-41 Induces ER Stress and Inhibits Tumor Progression in Inflammatory Breast CancerZenaida Fuentes, Gaurav Sharma, Bianca A Romo, et al.
Cancers|November 11, 2022
Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer GrowthLogan Blankenship, Uday P Pratap, Xue Yang, et al.
Cancer Letters|October 21, 2021
KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancerPrabhakar Pitta Venkata, Yihong Chen, Salvador Alejo, et al.
Breast Cancer Research : BCR|December 28, 2019
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancersSuryavathi Viswanadhapalli, Shihong Ma, Gangadhara Reddy Sareddy, et al.
Pageof 6